CCAAT/enhancer binding protein β deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis
Creators
- 1. Department of Pediatrics, School of Medicine, University of Colorado Denver, Aurora, CO 80045 (United States)
- 2. Division of Renal Diseases and Hypertension, School of Medicine, University of Colorado Denver, Aurora, CO 80045 (United States)
- 3. Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Denver, Aurora, CO 80045 (United States)
Description
Highlights: ► LXR agonist activation increases liver TG accumulation by increasing lipogenesis. ► C/EBPβ−/− mouse prevents LXR activation-mediated induction of hepatic lipogenesis. ► C/EBPβ deletion increases mitochondrial transport chain function. ► Beneficial effects of LXR activation on liver cholesterol metabolism did not change. ► C/EBPβ inhibition might have important therapeutic potential. -- Abstract: Drugs designed specifically to activate liver X receptors (LXRs) have beneficial effects on lowering cholesterol metabolism and inflammation but unfortunately lead to severe hepatic steatosis. The transcription factor CCAAT/enhancer binding protein beta (C/EBPβ) is an important regulator of liver gene expression but little is known about its involvement in LXR-based steatosis and cholesterol metabolism. The present study investigated the role of C/EBPβ expression in LXR agonist (T0901317)-mediated alteration of hepatic triglyceride (TG) and lipogenesis in mice. C/EBPβ deletion in mice prevented LXR agonist-mediated induction of lipogenic gene expression in liver in conjunction with significant reduction of liver TG accumulation. Surprisingly, C/EBPβ−/− mice showed a major increase in liver mitochondrial electron chain function compared to WT mice. Furthermore, LXR activation in C/EBPβ−/− mice increased the expression of liver ATP-binding cassette transporter ABCG1, a gene implicated in cholesterol efflux and reducing blood levels of total and LDL-cholesterol. Together, these findings establish a central role for C/EBPβ in the LXR-mediated steatosis and mitochondrial function, without impairing the influence of LXR activation on lowering LDL and increasing HDL-cholesterol. Inactivation of C/EBPβ might therefore be an important therapeutic strategy to prevent LXR activation-mediated adverse effects on liver TG metabolism without disrupting its beneficial effects on cholesterol metabolism.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2012.11.027Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2012.11.027;
- PII
- S0006-291X(12)02188-2;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 430
- Journal Issue
- 1
- Journal Page Range
- p. 336-339
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 45031297
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ATP; BLOOD; CHOLESTEROL; DRUGS; INFLAMMATION; INHIBITION; LIVER; METABOLISM; MICE; MITOCHONDRIA; RECEPTORS; TRANSCRIPTION FACTORS; TRIGLYCERIDES
- Descriptors DEC
- ANIMALS; BIOLOGICAL MATERIALS; BODY; BODY FLUIDS; CELL CONSTITUENTS; DIGESTIVE SYSTEM; ESTERS; GLANDS; HYDROXY COMPOUNDS; LIPIDS; MAMMALS; MATERIALS; MEMBRANE PROTEINS; NUCLEOTIDES; ORGANIC COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; PROTEINS; RODENTS; STEROIDS; STEROLS; SYMPTOMS; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.